Annexon, Inc. ANNX
4.19 USD -0.02 (-0.48%)
At closeNov 12, 2026, 4:04 AM EST
4.25 +0.06 +1.43%
Pre-market · Nov 12, 4:04 AM ET
4.14 Day range 4.28
2.54 52-week range 7.18
- YTD
- -16.53%
- 1 year
- +41.08%
News
benzinga.com Annexon Q3 EPS $(0.25) Beats $(0.28) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 32.43 percent increase over losses of $(0.37) per…
globenewswire.com Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission…
defenseworld.net Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug Annexon (NASDAQ: ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of…
benzinga.com Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026.…
benzinga.com Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.
benzinga.com HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25 HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.